Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Wed7,707.98+0.21%

Nasdaq · Wed26,331.09+0.16%

Dow · Wed53,463.05+0.22%

Russell 2000 · Wed3,032.94+0.50%

VIX · Wed14.89unchanged

U.S. 2Y / 10Y · 08:334.166% / 4.645%10Y −0.8 bp overnight

Dollar index · 08:3398.84near unchanged

WTI · 06:31 UTC$86.00+0.20%

Gold · 08:23$4,549.90+0.10%

Nikkei · 15:18 JST66,209+1.35%

Hang Seng · 14:18 HKT25,805+1.22%

Shanghai · 14:18 CST3,893.67−0.02%

KOSPI · 15:13 KST6,848.98+5.84%

Euro Stoxx 50 · Wed6,444.46Europe pre-open

DAX / FTSE · Wed26,091 / 10,743Europe pre-open

S&P / Nasdaq futures7,739 / 29,647+0.13% / +0.46%

1 · Policy relief

Treasury interrupts the bond rout

Treasury will at least double long-end liquidity-support buybacks from $2bn to at least $4bn per operation, effective Sep. 9 through Nov. 4. Official Aug. 19 closes fell to 4.65% (10Y) and 5.19% (30Y), from 4.71% and 5.28%. This is liquidity support—not debt paydown. Treasury · curve

2 · Divergence

Index rebound, AI still weak

The S&P rose 0.21%, but NVDA fell 0.99%, AVGO 4.61%, VRT 4.23% and CRDO 4.53%. By contrast AMZN gained 2.46%. The message is selective cloud/platform strength rather than a repaired semiconductor tape. CNBC S&P · NVDA quote

3 · Asia

Korea snaps back on SK Hynix action

KOSPI rebounded about 5.8%; SK Hynix surged more than 12% after accelerating a ₩40tn repurchase/cancellation program and targeting shareholder returns above 50% of cumulative 2025–27 free cash flow. This reverses part—not all—of Tuesday's semiconductor shock. CNBC live markets

Market drivers & session map

Macro, central banks & geopolitics

FOMC minutes: July minutes show staff-estimated inflation elevated by prior tariffs, Middle East energy/input costs and AI-buildout demand; market pricing at the meeting expected a September hike. This supports caution on long-duration multiples despite Wednesday's yield relief. Federal Reserve
Treasury mechanics: buybacks target 10–20Y and 20–30Y sectors. They improve liquidity but do not remove the underlying fiscal issuance, oil-inflation or hyperscaler-financing burden. Official release
Geopolitics: WTI remains around $86 and the Iran/Hormuz risk premium persists. Overnight U.S. “economic warfare” rhetoric adds headline and gap risk. CNBC
Today: weekly jobless claims and Walmart earnings arrive after this report's cutoff. Do not treat consensus or results as known at 08:30 Italy. Session preview

Global tape, earnings & rotation

U.S. breadth: all four headline indexes rose, with Russell 2000 (+0.50%) leading; VIX held 14.89. The rebound was modest relative to the prior semiconductor drawdown. CNBC Russell
Asia: Nikkei +1.35%, Hang Seng +1.22%, Shanghai −0.02% and KOSPI +5.84% at vendor timestamps. Korea's move is event-amplified by SK Hynix, not a uniform regional signal. CNBC global dashboard
Europe: still closed at cutoff. Wednesday references: Euro Stoxx 50 6,444.46, DAX 26,091.33, CAC 8,501.91, FTSE 10,743.35. Euro Stoxx quote
Rotation: XBI +5.90%, LLY +4.46%, AMLX +9.94% versus losses across AI infrastructure and pure-play quantum. Healthcare momentum is now strong but tactically extended. XBI quote

Theme dashboards

AI · weak breadth

Cloud wins; semis/power lag

Leader: AMZN +2.46% to $265.84. Q2 AWS sales rose 37% to $42.2bn and AWS operating income reached $16.6bn; AI and chips businesses each exceeded a $25bn annual run rate. Amazon IR
Laggards: NVDA −0.99%, AVGO −4.61%, VRT −4.23%, CRDO −4.53%; MU −0.39%. Higher financing costs and crowded positioning remain valuation risks.
Primary risk/catalyst: NVDA reports Aug. 26. Its new SEC filing validates 4.25 GW of demand but creates a capped $105bn contingent-support framework tied to OpenAI leases; optional support covers another 3.8 GW. SEC 8-K · IR calendar

Quantum · speculative

Commercial proof, poor tape

Tape: IONQ −1.72%, RGTI −4.01%, QBTS −1.08%; QTUM's displayed close was 150.20, down about 1.29% versus its prior reference.
Verified catalyst: D-Wave/DOCOMO's second production application cut daily-peak location-registration signals 65.3% and paging signals 7.0% in a representative 333-base-station problem, completed in roughly five minutes. SEC 8-K
Risk: contract economics were not disclosed. Production use does not establish durable gross margin or justify pure-play valuations; dilution, architecture risk and violent squeezes remain material.

Peptide biotech · extended

Strong validation, chase risk

Leaders: AMLX +9.94% to $38.60 for a second post-readout gain; LLY +4.46% to $1,280.34; NVO +1.68% to $46.48; XBI +5.90%.
Avexitide evidence: 78-patient randomized Phase 3 LUCIDITY met its FDA-agreed primary endpoint with 55% fewer composite Level 2/3 hypoglycemic events versus placebo through week 16 (p=0.000003); all secondaries met. No treatment-related serious AEs; common AEs included diarrhea and injection-site reactions. Amylyx · trial record
Financial/regulatory risk: cash/investments were $250.8m at Jun. 30 with company-guided runway into 2028; NDA targeted by year-end. Approval, labeling, launch, competition and dilution remain binary exposures. Q2 release

Ranked ideas — confirmation required; fewer is better

1Bullish

AMZN · Amazon (Nasdaq)

Risk class: mega-cap growth / capex-intensive · Classification: relative-strength long · Applicable horizon: day trade, 1–4 week swing and selective 3–12+ months. Direction is uncertain below confirmation.

Thesis/catalyst: $265.84 Wednesday, +2.46% while semiconductor infrastructure fell. AWS grew 37%, AWS operating profit rose to $16.6bn, and AI/chips run rates each exceeded $25bn—hard evidence that platform monetization is broadening.

Evidence / counterargument: earnings momentum and relative strength are favorable. Counter: trailing-12-month free cash flow was a $7.6bn outflow as AI capex surged; a $53.4bn Anthropic-related pre-tax gain inflated Q2 net income. Rich expectations and rates remain risks.

Entry/confirmation: hold $264–266, preferably clear $270 with Nasdaq breadth. Invalidation/downside: daily close below $257; next risk zone $250. Key risks: capex/FCF, cloud competition, regulation, consumer slowdown, rates.

Thesis Confidence 77

Risk 61

Opportunity 74

2Bullish on pullback

XBI · SPDR S&P Biotech ETF (NYSE Arca)

Risk class: diversified high-volatility biotech ETF · Classification: pullback long, never chase · Applicable horizon: 1–4 weeks; selective 3–12+ months. Near-term direction uncertain after +5.90%.

Thesis/catalyst: broad biotech participation and validated clinical catalysts have produced strong relative momentum without single-name trial concentration.

Evidence / counterargument: $169.55 Wednesday and the prior $160 confirmation were exceeded. Counter: a one-day 5.9% move is stretched; higher yields raise funding costs and policy/FDA shocks can reverse the basket.

Entry/confirmation: controlled pullback holding $165–167, or close above $171 after consolidation. Invalidation/downside: close below $160; next risk area $154. Key risks: clinical failures, dilution, pricing policy, reversal into tech.

Thesis Confidence 72

Risk 67

Opportunity 69

1Tactical bearish

NVDA · Nvidia (Nasdaq)

Risk class: mega-cap high-duration / event risk · Classification: avoid new longs; bearish only on confirmation · Applicable horizon: day trade and 1–4 weeks. Not a structural short; direction becomes highly uncertain into Aug. 26 earnings.

Thesis/catalyst: $217.56 Wednesday, −0.99%, underperforming a rising Nasdaq and closing below yesterday's $218 bearish trigger. AI breadth remains poor and the $105bn contingent-support framework adds counterparty/lease complexity.

Evidence / counterargument: weak relative strength and high long yields support compression. Counter: the 4.25 GW deployment is exceptional demand validation, and earnings can gap above any technical level.

Entry/confirmation: only below $216 with weak SOX breadth; do not press ahead of earnings. Invalidation: reclaim $222; stronger invalidation above $225. Short losses are unlimited. Risks: earnings upside, capex acceleration, squeeze, headline gaps.

Thesis Confidence 73

Risk 82

Opportunity 60

2Avoid / conditional short

IONQ · IonQ (NYSE)

Risk class: high-volatility speculative growth · Classification: avoid; bearish only after breakdown · Applicable horizon: day trade / 1–4 weeks. Direction remains uncertain above support.

Thesis/catalyst: $43.36 Wednesday, −1.72%, as pure-play quantum failed to join the index rebound. High discount rates and distant/uncertain cash flows leave valuation exposed.

Evidence / counterargument: RGTI and QBTS also fell, confirming weak theme breadth. Counter: government funding, contracts or technical milestones can trigger violent squeezes.

Entry/confirmation: bearish only below $42.50; stronger below prior $39.50 trigger. Invalidation: daily close above $46. No borrow availability or fee is implied; short loss is unlimited. Risks: squeeze, M&A, contracts, low fundamental visibility.

Thesis Confidence 67

Risk 87

Opportunity 55

Watchlist — no chase orders

Ticker / risk class	Classification & horizon	Thesis / evidence	Confirmation	Invalidation / risks	C / R / O
Watch AMLX Nasdaq · small/mid-cap clinical biotech; binary	Post-readout watch; 1–4 weeks / 3–12 months. Direction uncertain after two-day surge.	Phase 3 endpoint/statistics/safety compelling; NDA by year-end, cash runway guided into 2028.	Several-day base above $36, then volume-backed break over $39.	Below $33. Approval/label, launch, competition, dilution; penny/OTC labels do not apply.	84 / 89 / 73
Watch LLY NYSE · large-cap peptide/metabolic	Quality watch; 3–12+ months.	Peptide franchise exposure with strong relative tape; $1,280.34, +4.46%.	Consolidate above $1,250; breakout over $1,285 only with sector breadth.	Below $1,220. Trial, manufacturing, pricing, competition, valuation.	70 / 60 / 67
Watch QBTS Nasdaq · speculative quantum	Production-use watch; 1–4 weeks only.	DOCOMO deployment is concrete, but economics undisclosed; $19.32, −1.08%.	Reclaim $20 then close above $21.50 on volume.	Below $18.50. Dilution, valuation, architecture and contract-economics risk.	74 / 85 / 59
Watch CRDO Nasdaq · high-growth AI networking	Recovery watch; 1–4 weeks / selective 3–12 months.	AI interconnect exposure, but $234.82 and −4.53% confirms broken near-term breadth.	Stabilize, then reclaim $246; prefer falling 10Y yield.	Below $228. Customer concentration, valuation, capex-cycle reversal.	63 / 79 / 61
Watch XLE NYSE Arca · liquid energy ETF	Geopolitical hedge watch; day / 1–4 weeks.	WTI near $86, but ETF fell 0.16% to $63.58 and did not confirm yesterday's >$63.70 entry.	Close above $64 with oil holding $85.	Below $61.80 or WTI below $81. Diplomacy/ceasefire gap risk.	67 / 64 / 62

Changes versus the 2026-08-19 report

Regime: upgraded from risk-off to neutral/cautious after Treasury action lowered the official 10Y by 6 bp and 30Y by 9 bp and all four U.S. indexes closed higher. Not risk-on: oil rose and AI breadth remained weak.
XBI bullish paper call: the prior $159–160 hold / $161 breakout confirmation occurred; XBI closed $169.55 (+5.90%). The thesis worked, but today's classification changes to pullback only because chase risk rose.
NVDA tactical avoid: the prior bearish confirmation below $218 triggered with a $217.56 close. Keep it tactical and smaller because Aug. 26 earnings can invalidate technicals overnight.
IONQ conditional bearish: prior $39.50 breakdown did not trigger; no short call is counted as active. New first confirmation is $42.50.
XLE bullish paper call: prior entry required a hold above $63.70; close was $63.58, so it did not confirm. Downgraded to watch. AMLX exceeded $36 and LLY held above $1,225.73, but both are extended; no hindsight chase.

Important catalysts: next 7–30 days

Aug. 20 · before U.S. open — Walmart Q2; 14:30 CEST — jobless claims
Consumer/margin and labor checks. At this report cutoff neither result was available. CNBC session preview

Aug. 26 · 14:30 CEST — U.S. GDP second estimate + July income/outlays
Growth and inflation data can reverse the long-end relief. BEA

Aug. 26 · ~22:20 CEST results / 23:00 CEST call — NVIDIA FY27 Q2
Primary catalyst for AI compute, networking, memory, power and cooling; watch demand, margins, supply and the new contingent-support disclosure. NVIDIA IR

Aug. 28 · 16:00 CEST — preliminary payroll benchmark
Can alter the perceived labor baseline and Fed path. BLS

Sep. 3–4 — U.S. trade and August employment
Trade: Sep. 3 at 14:30 CEST; payrolls: Sep. 4 at 14:30 CEST. Major dollar/rates/equity catalysts. BEA · BLS

Sep. 9 — larger Treasury long-end buybacks begin
At least $4bn per operation in targeted 10–30Y sectors through Nov. 4. Liquidity help, not fiscal cure. Treasury

Sep. 15–16 — FOMC meeting
Inside the 30-day window and accompanied by projections. Oil, tariffs and term premium make policy direction unusually consequential. Fed calendar

Bottom line by horizon

Day trade

Bias: mildly constructive while S&P futures hold 7,729 and 10Y stays below 4.67%; prefer AMZN/platform relative strength and avoid chasing XBI/AMLX gaps.

Biggest risk: oil/geopolitical headline or weak U.S. data. Invalidation: S&P futures below 7,700 with 10Y back above 4.70%.

1–4 week swing

Bias: selective, not broad risk-on: AMZN and XBI-on-pullback versus reduced speculative quantum/weak AI suppliers. Keep event sizing small before NVDA.

Biggest risk: Treasury relief fades because issuance/inflation dominate. Invalidation: 10Y sustains above 4.75%, AMZN below $257, XBI below $160.

3–12+ month investment

Bias: no compelling full-size theme entry today. AMZN offers monetized AI exposure; LLY is quality peptide exposure; AMLX remains binary despite strong Phase 3 data.

Biggest risk: paying peak expectations amid rising discount rates/capex. Invalidation: earnings/FCF deterioration, trial/regulatory setbacks, or durable long-end repricing higher.

Data quality & methodology

High-confidence primary data: U.S. Treasury curve and buyback release, Fed minutes/calendar, BEA/BLS calendars, SEC filings, company IR releases and ClinicalTrials.gov.
Market data: CNBC quote pages and global banner queried between 08:31 and 08:34 CEST. Index/futures fields were cross-checked against CNBC's live-market article. Overnight instruments are indicative and timestamps differ by venue.
Vendor limitation: CNBC equity-page embedded data displayed Wednesday closing values but some equity metadata carried an Aug. 18 date; AMZN's $265.84 was independently confirmed by Amazon IR as Aug. 19. The report labels the values Wednesday based on the session article and close sequence, while retaining this caveat.
Europe: 08:30 CEST precedes the 09:00 CEST main cash open; Wednesday references are clearly separated from live Asian/futures indications.
Unavailable source paths: Yahoo chart API returned HTTP 429; Stooq quote endpoint returned HTTP 404 for all tested instruments; interactive SEC EDGAR search hit its request threshold. Alternatives succeeded: CNBC quote pages, official Treasury CSV, SEC submissions/filing URLs, company IR and ClinicalTrials.gov API. No material dashboard field is declared unavailable.
Scores: Thesis Confidence measures evidence quality—not guaranteed probability. Risk is higher when riskier. Levels are paper-tracking research triggers, not automatic orders.

Aman's Global Market Intelligence — 2026-08-20